Market closed
Harmony Biosciences/$HRMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ticker
$HRMY
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
268
Website
HRMY Metrics
BasicAdvanced
$1.6B
11.34
$2.51
0.82
-
Price and volume
Market cap
$1.6B
Beta
0.82
52-week high
$40.93
52-week low
$26.47
Average daily volume
739K
Financial strength
Current ratio
3.308
Quick ratio
3.143
Long term debt to equity
24.856
Total debt to equity
27.521
Interest coverage (TTM)
10.91%
Management effectiveness
Return on assets (TTM)
13.17%
Return on equity (TTM)
25.84%
Valuation
Price to earnings (TTM)
11.339
Price to revenue (TTM)
2.265
Price to book
2.47
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
8.425
Growth
Revenue change (TTM)
22.80%
Earnings per share change (TTM)
17.84%
3-year revenue growth (CAGR)
32.76%
3-year earnings per share growth (CAGR)
62.96%
What the Analysts think about HRMY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
HRMY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HRMY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HRMY News
AllArticlesVideos
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
Business Wire·2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out
Accesswire·2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Harmony Biosciences stock?
Harmony Biosciences (HRMY) has a market cap of $1.6B as of April 19, 2025.
What is the P/E ratio for Harmony Biosciences stock?
The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 11.34 as of April 19, 2025.
Does Harmony Biosciences stock pay dividends?
No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Harmony Biosciences dividend payment date?
Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Harmony Biosciences?
Harmony Biosciences (HRMY) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.